MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Scientific Trial of MYMD-1 as a Treatment for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Firm”), a clinical stage pharmaceutical company committed to prolonging healthy life expectancy, today announced that the very first individual has been enrolled in the Firm’s Phase 2 medical test of lead prospect MYMD-1, an oral immune regulator medication, as a therapy for postponing aging and also broadening healthy life-span.

The primary endpoint for the Phase 2 double-blind, placebo-controlled scientific test is to achieve a decrease in the distributing levels of (TNF-α), lump necrosis aspect receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the proteins in the body that cause swelling as well as assist trigger the procedure of aging. The secondary actions of the trial will be the security, tolerability, as well as pharmacokinetics in this populace of people.

” In a Phase 1 professional test of MYMD-1, we demonstrated the drug’s statistically substantial efficiency in minimizing levels of TNF-α, a principal in creating pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the primary endpoint for our Phase 2 research, which our company believe positions us well for a successful Stage 2 result,” said Chris Chapman, M.D., President, Supervisor and Principal Medical Officer of MyMD. “The initiation of client enrollment in this research advancements our mission to slow down the aging process, protect against loss of muscle mass tissue in aging, limit frailty, and extend healthy and balanced lifespan.”

MyMD has actually mentioned that there are no FDA-approved medicines for dealing with aging problems and prolonging healthy lifespan human beings, a market expected to be a minimum of $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are one of the most proposed drugs by profits, a global market of approximately $40 billion annually,2 and, according to Nature Aging journal,3 a slowdown in maturing that would certainly increase life span by one year is worth $38 trillion and also by 10 years deserves $367 trillion.

In addition to aging, MYMD-1’s unique activity in regulating the body immune system and dealing with persistent inflammation is being created for the therapy of autoimmune illness, consisting of rheumatoid arthritis (RA), several sclerosis (MS), diabetes, and inflammatory digestive tract condition.

” We intend to begin writing procedures for a Stage 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The climbing occurrence of rheumatoid arthritis as well as other autoimmune as well as inflammatory diseases are driving demand for TNF preventions like MYMD-1, and also our company believe our orally provided medicine with very low toxicity would be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”

Rheumatoid joint inflammation affects roughly 40 million people worldwide.4.

Regarding MYMD-1.

Initially created for autoimmune conditions, MYMD-1’s main objective is to slow down the aging process, stop sarcopenia as well as frailty, as well as expand healthy life expectancy. Because it can cross the blood-brain barrier as well as gain access to the main nerve system (CNS), MYMD-1 is also placed to be a feasible therapy for brain-related disorders. Its device of activity and efficiency in diseases including numerous sclerosis (MS) and thyroiditis have been examined through collaborations with a number of scholastic institutions. MYMD-1 is also showing pledge in pre-clinical researches as a prospective therapy for post- COVID-19 issues and also as an anti-fibrotic and anti-proliferation therapeutic.

MYMD-1 has revealed effectiveness in pre-clinical studies in controling the immune system by carrying out as a careful inhibitor of tumor necrosis factor-alpha (TNF-α), a motorist of chronic swelling. Unlike various other therapies, MYMD-1 has actually been received these pre-clinical research studies to uniquely obstruct TNF-α when it comes to be overactivated in autoimmune conditions as well as cytokine tornados, but not block it from doing its typical task of being a very first -responder to any regular sort of modest infection. MYMD-1’s simplicity of dental application is another differentiator contrasted to currently readily available TNF-α blockers, all of which need distribution by shot or infusion. No accepted TNF prevention has ever before been dosed orally. Furthermore, the medication is not immunosuppressive and has not been revealed to create the significant adverse effects typical with standard treatments that treat inflammation.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific stage pharmaceutical company devoted to expanding healthy lifespan, is focused on creating 2 unique restorative systems that treat the root causes of condition as opposed to just attending to the signs and symptoms. MYMD-1 is a medication system based upon a medical stage small particle that regulates the immune system to control TNF-α, which drives persistent inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, rise longevity, and also treat autoimmune illness and also COVID-19- associated depression. The Business’s second medicine system, Supera-CBD, is being developed to deal with chronic pain, addiction and epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) as well as is being created to deal with as well as improve upon the rapidly growing CBD market, which includes both FDA authorized medications and also CBD products not currently controlled as medications. To find out more, see www.mymd.com.